 Joshua Melson
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 27 | 2022 | 125 | 12.540 |
Why?
| | Adenoma | 15 | 2022 | 63 | 9.200 |
Why?
| | Colonoscopy | 28 | 2022 | 88 | 9.130 |
Why?
| | Colonic Polyps | 11 | 2022 | 36 | 5.750 |
Why?
| | Early Detection of Cancer | 13 | 2020 | 91 | 3.900 |
Why?
| | Neoplasms, Second Primary | 5 | 2022 | 42 | 3.190 |
Why?
| | Mass Screening | 8 | 2021 | 199 | 2.350 |
Why?
| | DNA Methylation | 5 | 2022 | 168 | 2.070 |
Why?
| | Capsule Endoscopy | 2 | 2021 | 5 | 1.660 |
Why?
| | Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.520 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2018 | 40 | 1.300 |
Why?
| | Adenomatous Polyps | 3 | 2017 | 7 | 1.260 |
Why?
| | Humans | 50 | 2022 | 31481 | 1.260 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2021 | 12 | 1.250 |
Why?
| | Colon | 4 | 2018 | 155 | 1.220 |
Why?
| | Guideline Adherence | 2 | 2016 | 77 | 1.130 |
Why?
| | Barrett Esophagus | 2 | 2020 | 19 | 0.980 |
Why?
| | Gastroenterology | 3 | 2019 | 16 | 0.950 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 61 | 0.940 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2022 | 4 | 0.920 |
Why?
| | Middle Aged | 21 | 2021 | 11209 | 0.910 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2022 | 30 | 0.890 |
Why?
| | Intestine, Small | 1 | 2021 | 37 | 0.830 |
Why?
| | Esophageal and Gastric Varices | 1 | 2020 | 2 | 0.810 |
Why?
| | Carcinoma | 2 | 2022 | 84 | 0.790 |
Why?
| | Poverty Areas | 1 | 2019 | 10 | 0.750 |
Why?
| | Quality of Health Care | 2 | 2022 | 141 | 0.750 |
Why?
| | Censuses | 1 | 2019 | 8 | 0.750 |
Why?
| | Clinical Competence | 3 | 2016 | 274 | 0.740 |
Why?
| | Aged | 17 | 2021 | 10295 | 0.680 |
Why?
| | Alcohol Withdrawal Delirium | 2 | 2015 | 2 | 0.670 |
Why?
| | Male | 20 | 2021 | 17583 | 0.670 |
Why?
| | Female | 20 | 2021 | 18253 | 0.660 |
Why?
| | Residence Characteristics | 1 | 2019 | 226 | 0.650 |
Why?
| | Cecum | 1 | 2016 | 10 | 0.640 |
Why?
| | Population Surveillance | 1 | 2018 | 127 | 0.640 |
Why?
| | Lymphoid Tissue | 1 | 2016 | 22 | 0.630 |
Why?
| | Pancreatic Neoplasms | 2 | 2020 | 181 | 0.620 |
Why?
| | Adenocarcinoma | 2 | 2019 | 237 | 0.610 |
Why?
| | Unnecessary Procedures | 1 | 2016 | 30 | 0.610 |
Why?
| | Colorectal Surgery | 1 | 2015 | 7 | 0.570 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 39 | 0.560 |
Why?
| | Colonic Neoplasms | 3 | 2022 | 84 | 0.560 |
Why?
| | Hyperplasia | 3 | 2021 | 26 | 0.550 |
Why?
| | Restraint, Physical | 1 | 2014 | 23 | 0.520 |
Why?
| | Patient Transfer | 1 | 2014 | 24 | 0.510 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 18 | 0.510 |
Why?
| | Patient Compliance | 1 | 2015 | 200 | 0.490 |
Why?
| | Risk Factors | 5 | 2021 | 2664 | 0.490 |
Why?
| | Diagnostic Errors | 1 | 2013 | 48 | 0.480 |
Why?
| | Retrospective Studies | 8 | 2020 | 3591 | 0.460 |
Why?
| | Ethanol | 1 | 2014 | 138 | 0.460 |
Why?
| | Intensive Care Units | 1 | 2014 | 316 | 0.420 |
Why?
| | Critical Care | 1 | 2014 | 234 | 0.420 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 389 | 0.420 |
Why?
| | Colectomy | 1 | 2010 | 33 | 0.410 |
Why?
| | Intestinal Mucosa | 4 | 2022 | 235 | 0.400 |
Why?
| | Cohort Studies | 5 | 2018 | 2014 | 0.400 |
Why?
| | Colitis, Ulcerative | 1 | 2010 | 74 | 0.390 |
Why?
| | Neoplasm Staging | 6 | 2020 | 481 | 0.380 |
Why?
| | Prospective Studies | 4 | 2021 | 1934 | 0.380 |
Why?
| | Chi-Square Distribution | 3 | 2015 | 178 | 0.360 |
Why?
| | United States | 4 | 2020 | 2539 | 0.330 |
Why?
| | Biopsy | 3 | 2020 | 283 | 0.330 |
Why?
| | Logistic Models | 3 | 2015 | 479 | 0.330 |
Why?
| | Incidence | 3 | 2019 | 829 | 0.330 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 55 | 0.330 |
Why?
| | Gastrointestinal Diseases | 1 | 2007 | 42 | 0.320 |
Why?
| | Area Under Curve | 2 | 2019 | 79 | 0.310 |
Why?
| | Esophagoscopy | 3 | 2021 | 18 | 0.300 |
Why?
| | Academic Medical Centers | 2 | 2016 | 158 | 0.270 |
Why?
| | Risk Assessment | 4 | 2020 | 806 | 0.260 |
Why?
| | Severity of Illness Index | 1 | 2007 | 1240 | 0.230 |
Why?
| | Esophageal pH Monitoring | 1 | 2021 | 2 | 0.230 |
Why?
| | Prognosis | 4 | 2018 | 1028 | 0.220 |
Why?
| | Zenker Diverticulum | 1 | 2021 | 1 | 0.220 |
Why?
| | MicroRNAs | 1 | 2022 | 63 | 0.220 |
Why?
| | Endosonography | 2 | 2020 | 15 | 0.220 |
Why?
| | Gastrointestinal Transit | 1 | 2021 | 14 | 0.210 |
Why?
| | Esophagus | 1 | 2021 | 60 | 0.210 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 27 | 0.210 |
Why?
| | Adult | 6 | 2020 | 9779 | 0.210 |
Why?
| | Pancreatitis, Chronic | 1 | 2020 | 2 | 0.210 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2021 | 29 | 0.210 |
Why?
| | Pancreatic Cyst | 1 | 2020 | 5 | 0.210 |
Why?
| | Ikaros Transcription Factor | 1 | 2020 | 2 | 0.210 |
Why?
| | Transaminases | 1 | 2020 | 9 | 0.210 |
Why?
| | Treatment Outcome | 4 | 2020 | 3910 | 0.210 |
Why?
| | Gastroparesis | 1 | 2020 | 4 | 0.210 |
Why?
| | Observer Variation | 1 | 2020 | 146 | 0.200 |
Why?
| | Magnets | 1 | 2020 | 2 | 0.200 |
Why?
| | Epithelial Cells | 2 | 2013 | 101 | 0.200 |
Why?
| | Feasibility Studies | 1 | 2021 | 281 | 0.200 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.200 |
Why?
| | Bariatric Surgery | 1 | 2020 | 43 | 0.190 |
Why?
| | Appointments and Schedules | 1 | 2019 | 15 | 0.190 |
Why?
| | Aged, 80 and over | 5 | 2020 | 5234 | 0.190 |
Why?
| | Databases, Factual | 1 | 2021 | 391 | 0.190 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 2 | 0.180 |
Why?
| | Precancerous Conditions | 1 | 2018 | 27 | 0.180 |
Why?
| | ROC Curve | 1 | 2019 | 153 | 0.180 |
Why?
| | Forecasting | 1 | 2019 | 134 | 0.180 |
Why?
| | Quality Improvement | 1 | 2020 | 173 | 0.180 |
Why?
| | Colonoscopes | 1 | 2018 | 1 | 0.180 |
Why?
| | Genetic Testing | 1 | 2018 | 73 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2014 | 2028 | 0.170 |
Why?
| | Reproducibility of Results | 1 | 2020 | 886 | 0.170 |
Why?
| | Referral and Consultation | 1 | 2018 | 99 | 0.170 |
Why?
| | Clinical Protocols | 2 | 2015 | 75 | 0.160 |
Why?
| | Sex Factors | 2 | 2018 | 542 | 0.160 |
Why?
| | CpG Islands | 1 | 2017 | 53 | 0.160 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 81 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2017 | 41 | 0.160 |
Why?
| | Alcoholism | 2 | 2015 | 90 | 0.160 |
Why?
| | Brain Neoplasms | 1 | 2018 | 187 | 0.160 |
Why?
| | Portal Vein | 1 | 2017 | 47 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2017 | 73 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 95 | 0.150 |
Why?
| | Documentation | 1 | 2016 | 27 | 0.150 |
Why?
| | Age Factors | 2 | 2018 | 943 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 82 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2017 | 117 | 0.150 |
Why?
| | Staff Development | 1 | 2015 | 29 | 0.140 |
Why?
| | Hospitals, Community | 1 | 2015 | 21 | 0.140 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 28 | 0.140 |
Why?
| | Nursing Staff, Hospital | 1 | 2015 | 71 | 0.140 |
Why?
| | Microsatellite Instability | 1 | 2014 | 9 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2013 | 687 | 0.130 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 580 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2015 | 364 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 986 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 85 | 0.130 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2014 | 39 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 637 | 0.130 |
Why?
| | Internship and Residency | 1 | 2016 | 201 | 0.120 |
Why?
| | Colitis | 1 | 2013 | 34 | 0.120 |
Why?
| | Mast Cells | 1 | 2013 | 45 | 0.120 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 50 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 68 | 0.120 |
Why?
| | Macrophages | 1 | 2013 | 129 | 0.110 |
Why?
| | Time Factors | 1 | 2016 | 1902 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 156 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 891 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2007 | 40 | 0.080 |
Why?
| | Drug Resistance | 1 | 2007 | 68 | 0.080 |
Why?
| | Diarrhea | 1 | 2007 | 50 | 0.080 |
Why?
| | Immunohistochemistry | 2 | 2019 | 494 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 100 | 0.080 |
Why?
| | Acute Disease | 1 | 2007 | 254 | 0.080 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2007 | 116 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2007 | 163 | 0.080 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 292 | 0.080 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 104 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2010 | 1452 | 0.070 |
Why?
| | Apoptosis | 1 | 2007 | 292 | 0.070 |
Why?
| | Reoperation | 1 | 2010 | 938 | 0.070 |
Why?
| | Fecal Incontinence | 1 | 2005 | 9 | 0.070 |
Why?
| | Geriatric Assessment | 1 | 2005 | 232 | 0.060 |
Why?
| | Carcinogenesis | 1 | 2022 | 27 | 0.060 |
Why?
| | Manometry | 1 | 2021 | 28 | 0.060 |
Why?
| | Endoscopes | 1 | 2021 | 14 | 0.050 |
Why?
| | Pylorus | 1 | 2020 | 2 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 10 | 0.050 |
Why?
| | Gastric Emptying | 1 | 2020 | 15 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2020 | 54 | 0.050 |
Why?
| | Gastroplasty | 1 | 2020 | 28 | 0.050 |
Why?
| | Inventions | 1 | 2019 | 4 | 0.050 |
Why?
| | Epidemiological Monitoring | 1 | 2019 | 8 | 0.050 |
Why?
| | Biomedical Technology | 1 | 2019 | 9 | 0.050 |
Why?
| | Canada | 1 | 2019 | 57 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2019 | 10 | 0.050 |
Why?
| | Gastric Bypass | 1 | 2020 | 56 | 0.050 |
Why?
| | Diffusion of Innovation | 1 | 2019 | 41 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 42 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2019 | 68 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2020 | 82 | 0.050 |
Why?
| | Microscopy, Confocal | 1 | 2019 | 128 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 236 | 0.050 |
Why?
| | Internationality | 1 | 2018 | 26 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2018 | 102 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2018 | 117 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 49 | 0.040 |
Why?
| | Societies, Medical | 1 | 2019 | 209 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 233 | 0.040 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.040 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 2 | 0.040 |
Why?
| | Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 390 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2018 | 113 | 0.040 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2017 | 5 | 0.040 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2017 | 6 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 22 | 0.040 |
Why?
| | Disease Progression | 1 | 2019 | 861 | 0.040 |
Why?
| | Focus Groups | 1 | 2015 | 93 | 0.040 |
Why?
| | Educational Measurement | 1 | 2015 | 66 | 0.040 |
Why?
| | Quality of Life | 1 | 2020 | 663 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 11 | 0.030 |
Why?
| | ras Proteins | 1 | 2014 | 14 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 23 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 39 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 110 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 113 | 0.030 |
Why?
| | Piroxicam | 1 | 2013 | 6 | 0.030 |
Why?
| | HT29 Cells | 1 | 2013 | 10 | 0.030 |
Why?
| | Chromones | 1 | 2013 | 9 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2013 | 8 | 0.030 |
Why?
| | Tryptases | 1 | 2013 | 10 | 0.030 |
Why?
| | Morpholines | 1 | 2013 | 16 | 0.030 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 39 | 0.030 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 41 | 0.030 |
Why?
| | Cell Movement | 1 | 2013 | 119 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 290 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2013 | 232 | 0.030 |
Why?
| | Mutation | 1 | 2014 | 464 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2013 | 399 | 0.030 |
Why?
| | Rectum | 1 | 2011 | 72 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 108 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 548 | 0.030 |
Why?
| | Signal Transduction | 1 | 2013 | 588 | 0.020 |
Why?
| | Mice | 1 | 2013 | 1894 | 0.020 |
Why?
| | African Americans | 1 | 2014 | 818 | 0.020 |
Why?
| | Psychotropic Drugs | 1 | 2005 | 30 | 0.020 |
Why?
| | Causality | 1 | 2005 | 58 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2005 | 124 | 0.020 |
Why?
| | Health Surveys | 1 | 2005 | 102 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2005 | 150 | 0.020 |
Why?
| | Comorbidity | 1 | 2005 | 562 | 0.020 |
Why?
| | Animals | 1 | 2013 | 5312 | 0.020 |
Why?
| | Chicago | 1 | 2005 | 955 | 0.010 |
Why?
| | Stroke | 1 | 2005 | 367 | 0.010 |
Why?
|
|
Melson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|